← Leaderboards
Pavel Sumazin
Baylor College Of Medicine
$795,451
Attributed
$795,451
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $225.1K · FY2019–25$250K$187.5K$125K$62.5K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$795,451 · 2
By mechanism
R21$795,451 · 2
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Anil Kumar Jaiswal$15,017,310
- Andras A. Heczey$2,725,684
- Bryan Michael Burt$3,339,861
- C P Steuber$1,047,551
- Arun Sreekumar$9,871,133
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularTreatment StrategyDiagnosisInnovationPrimary Carcinoma Of The Liver CellsTreatment ResponseChildhood Liver CancerDesignHepatoblastomaImproved OutcomePredictive MarkerBiological MarkersSamplingTechnologyCellsChildClinical TrialsCombination Drug TherapyDiagnosticExcisionCancer PatientHigh RiskPersonalized MedicineTumor
Grant awards (4)
Discovery of chemoresistant tumor subclones in pediatric liver cancers$187,567
R21 · FY2025 · CA · contact PI
Discovery of chemoresistant tumor subclones in pediatric liver cancers$225,084
R21 · FY2024 · CA · contact PI
Diagnostic biomarkers for hepatoblastomas with hepatocellular carcinoma features$174,000
R21 · FY2020 · CA · contact PI
Diagnostic biomarkers for hepatoblastomas with hepatocellular carcinoma features$208,800
R21 · FY2019 · CA · contact PI